Equities Analysts Offer Predictions for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at Zacks Research reduced their Q1 2026 earnings per share (EPS) estimates for shares of Biogen in a report issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $3.49 per share for the quarter, down from their prior forecast of $3.59. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q2 2026 earnings at $4.30 EPS, Q3 2026 earnings at $4.07 EPS, Q4 2026 earnings at $4.09 EPS, FY2026 earnings at $15.96 EPS and FY2027 earnings at $16.84 EPS.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Several other equities analysts have also recently commented on the company. Canaccord Genuity Group reduced their target price on Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Stifel Nicolaus cut Biogen from a “buy” rating to a “hold” rating and set a $175.00 target price for the company. in a research note on Monday, December 16th. Royal Bank of Canada reduced their target price on Biogen from $231.00 to $225.00 and set an “outperform” rating for the company in a research note on Thursday, February 13th. Jefferies Financial Group cut Biogen from a “buy” rating to a “hold” rating and reduced their target price for the company from $250.00 to $180.00 in a research note on Monday, December 9th. Finally, Bank of America reiterated a “neutral” rating and set a $178.00 target price on shares of Biogen in a research note on Tuesday, December 10th. Seventeen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $213.33.

Biogen Stock Down 0.4 %

NASDAQ BIIB opened at $139.44 on Friday. The stock has a market cap of $20.41 billion, a PE ratio of 12.46, a P/E/G ratio of 1.51 and a beta of 0.01. Biogen has a fifty-two week low of $128.51 and a fifty-two week high of $238.00. The business has a 50 day moving average price of $143.09 and a two-hundred day moving average price of $164.57. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Inspire Trust Co. N.A. increased its holdings in shares of Biogen by 58.5% during the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock valued at $2,113,000 after purchasing an additional 4,025 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Biogen by 0.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock valued at $6,646,000 after purchasing an additional 111 shares during the period. Centre Asset Management LLC increased its holdings in shares of Biogen by 7.7% during the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock valued at $7,880,000 after purchasing an additional 3,698 shares during the period. Amundi increased its holdings in shares of Biogen by 35.6% during the fourth quarter. Amundi now owns 1,216,990 shares of the biotechnology company’s stock valued at $183,461,000 after purchasing an additional 319,478 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Biogen by 1.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company’s stock valued at $176,982,000 after purchasing an additional 12,319 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the sale, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by corporate insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.